C53.1 ICD-10-CM Code: Malignant neoplasm of exocervix
C53.1 maps to CMS-HCC V28 22. A source-labeled RAF reference is available. Documentation must support MEAT. MEAT criteria · RAF Calculator · free HCC coding tools
HCC Buddy Code Card
Digital ICD-10 code-book layout with official code detail, always-visible risk models, Code Trumping, and Buddy coding guidance.
FY 2026 Apr update / Neoplasms (C00-D49) / Malignant neoplasms of female genital organs (C51-C58)
C53.1
Billable / SpecificICD-10-CMOfficial ICD-10-CMCodebook guidanceMalignant neoplasm of exocervix
Cancer that occurs in the exocervix, the outer portion of the cervix that is visible during examination.
Buddy Insight
Malignant neoplasm of the exocervix involves the outer portion of the cervix that is visible during speculum examination.
CMS-HCC V28
MappedHCC 22
Code-level coefficient reference
CMS-HCC V24
HistoricalHistorical
Not used for CY2026 payment
ACA/HHS
MappedHCC 012
Code-level coefficient reference
ESRD/PACE
MappedHCC 11
Code-level coefficient reference
RXHCC
N/A—
Not mapped
Code Book Path
Inclusion Terms
OfficialICD-10-CM does not list inclusion terms for C53.1 in this effective period.
Excludes 2
OfficialICD-10-CM does not list Excludes 2 notes for C53.1 in this effective period.
Related Child Codes
Includes
OfficialICD-10-CM does not list Includes notes for C53.1 in this effective period.
Excludes 1
Official- carcinoma in situ of cervix uteri (D06.-)
Code First
OfficialICD-10-CM does not list Code First sequencing instructions for C53.1 in this effective period.
Use Additional
OfficialICD-10-CM does not list Use Additional Code instructions for C53.1 in this effective period.
Code Also
OfficialICD-10-CM does not list Code Also instructions for C53.1 in this effective period.
Buddy Documentation Tip
MEAT Support
Audit Caution
Common Mistakes
Current with CMS: FY2026 ICD-10-CM Apr 1 update (effective Apr 1 – Sep 30, 2026) · CMS-HCC V28, 100% phased in for payment year 2026. FY2027 code set already staged for October 1, 2026. How HCC Buddy stays current →
Is C53.1 an HCC code?
Yes. C53.1 (Malignant neoplasm of exocervix) maps to HCC 22, Bladder, Colorectal, and Other Cancers under the CMS-HCC V28 risk adjustment model, with a source-labeled community non-dual aged reference coefficient of 0.363. Source-labeled code-level coefficients are references, not member totals. Actual contribution depends on complete member context, hierarchy and cleanup rules, interactions, and model year. HCC Buddy's RAF Calculator supports CMS-HCC V28 PY2026 and shows no score unless every required source and calculation check passes. It is billable for payment year 2026.
Coder answer: C53.1 is billable and maps to V28 HCC 22, Bladder, Colorectal, and Other Cancers. Open it in the Code Book for the tabular path, RAF, and MEAT checklist.
- Code
- C53.1
- Description
- Malignant neoplasm of exocervix
- HCC (V28)
- HCC 22 — Bladder, Colorectal, and Other Cancers
- RAF reference coefficient
- 0.363
- Billable
- Yes
- Payment year
- 2026
HCC Category Mapping
These are source-labeled model coefficients, not member totals. A category may still be removed by hierarchy or model cleanup rules. Weights are not directly comparable across models: CMS-HCC V28 and V24 use Community, Non-Dual, Aged; ESRD uses the dialysis continuing-enrollee model; RxHCC is the Part D continuing-enrollee, non-low-income, aged weight (a larger scale than CMS-HCC). ACA/HHS has no single weight — it varies by metal level. Actual per-patient RAF contribution depends on member context, hierarchy and cleanup rules, interactions, and the model year used by the payer. V28 is the CMS-HCC model phased in over payment years 2024–2026; V24 remains available for historical review.
Work C53.1 in the Code Book — tabular path, V28 RAF reference, and MEAT checklist →
MEAT Criteria for C53.1
For C53.1 to count as a valid HCC diagnosis in a given encounter, the provider's documentation must show MEAT: Monitor, Evaluate, Assess, or Treat. A diagnosis from a prior year does not carry forward automatically, it has to be re-documented and supported each calendar year.
- MMonitor: signs, symptoms, disease progression, or lab trending documented in the note
- EEvaluate: test results, medication response, or physical findings reviewed by the provider
- AAssess: explicit mention in the assessment or plan with acknowledgment of status
- TTreat: medication, referral, procedure, therapy, or counseling tied to the diagnosis
Only one of M/E/A/T is required to support the code, but the documentation must be specific enough to show that the provider actually addressed C53.1 during that encounter, not just copy-forwarded from a problem list.
Coder workflow notes
Get the V28 mapping + MEAT cheat sheet
One printable reference: check representative V28 mappings and the documentation reminders your note needs. Free, no card.
Free PDF. No card. Unsubscribe anytime.
What This Code Means
C53.1 is the ICD-10-CM diagnosis code for malignant neoplasm of exocervix. Cancer that occurs in the exocervix, the outer portion of the cervix that is visible during examination. C53.1 sits in the ICD-10-CM chapter for neoplasms (c00-d49), within the section covering malignant neoplasms of female genital organs (c51-c58).
Under the CMS-HCC V28 risk adjustment model, C53.1 maps to Bladder, Colorectal, and Other Cancers (HCC 22) with a source-labeled community, non-dual, aged reference coefficient of 0.363. No V24 mapping is shown for C53.1; use the applicable model and payment year when reviewing the V28 mapping. V28 is the CMS-HCC risk adjustment model that reached 100% phase-in for payment year 2026, replacing V24 which was used during the PY2024–PY2025 transition. Source-labeled code-level coefficients are references, not member totals. Actual contribution depends on complete member context, hierarchy and cleanup rules, interactions, and model year. HCC Buddy's RAF Calculator supports CMS-HCC V28 PY2026 and shows no score unless every required source and calculation check passes.
Squamous cell carcinoma is the predominant histology; verify and document the specific type. Because C53.1 maps to an HCC category, the provider's documentation must satisfy MEAT criteria (Monitor, Evaluate, Assess, or Treat) before the diagnosis is used for risk adjustment. When documentation is ambiguous, coders should issue a provider query rather than assume the highest-specificity variant.
HCC Buddy maintains structured V28 and V24 mapping, source-labeled coefficient references, and MEAT documentation criteria for C53.1 sourced directly from the CMS-HCC risk adjustment model files and the CMS ICD-10-CM code set.
Coding Tips
- •Squamous cell carcinoma is the predominant histology; verify and document the specific type
- •This is the most common site for cervical cancer; ensure HPV status is documented when available
Clinical Significance
Malignant neoplasm of the exocervix involves the outer portion of the cervix that is visible during speculum examination. Exocervical cancers are predominantly squamous cell carcinomas and are strongly associated with Human Papillomavirus infection. This is the most common location for cervical cancer and the area most effectively screened by Pap smear and colposcopy.
Documentation Requirements
- ✓Specific site confirmed as exocervix (ectocervix or portio vaginalis)
- ✓Histological type (squamous cell carcinoma predominates)
- ✓FIGO staging
- ✓Depth of stromal invasion
- ✓Parametrial involvement assessment
- ✓Lymph node status
- ✓Human Papillomavirus status and type if documented
Commonly Confused Codes
- •C53.0: Malignant neoplasm of endocervix; inner canal versus outer surface: different sites with different predominant histologies
- •C53.8: Overlapping sites of cervix; use when tumor involves both endocervix and exocervix
- •C53.9: Cervix uteri, unspecified; use only when exocervix is not specifically identified
- •D06.0/D06.1: Carcinoma in situ of cervix; preinvasive disease: not the same as invasive cancer